title: [Present and future of kidney transplantation].
abstract: Renal transplant is the treatment of choice for the patient with end stage renal disease. Spain is the country with the highest donation rate (33 ppm). However, at present this figure is stabilized. The development of non-beating heart programmes, living-donor nephrectomy (specially laparoscopic nephrectomy) programmes, and may be xenotransplantation in a non-immediate future could increase the transplantation activity. The knowledge of preservation mechanisms, specially with the use of perfusion machines allows to rescue for transplantation kidneys with a long warm-ischemia time. Furthermore, these machines are useful for analyzing viability markers. The new immunosuppressive drugs: Tacrolimus, Mycophenolate-Mophetil, Rapamycin and monoclonal antibodies against alpha chain of the interleukine-2 receptor (Basoliximab and Dazcizumab) have reduced the incidence of acute rejection in the immediate renal transplant period. However, its effect in the long-term follow-up period is still a matter of controversy. The incidence of tumour in the renal transplant recipient is increased, specially those of lymphoma, skin cancer and Kaposi sarcoma. Periodical exams for detecting the development of tumours are mandatory in this population. Finally, xenotransplantation is an attractive alternative, although immunological, infective and ethical barriers should previously be resolved.
authors.affiliation: Servicio de Urología, Hospital Ramón y Cajal, Universidad Alcalá, Madrid.
authors.forename: F J
authors.initials: FJ
authors.lastname: Burgos
authors.forename: A
authors.initials: A
authors.lastname: Alcaraz
authors.forename: I
authors.initials: I
authors.lastname: Castillón
authors.forename: M
authors.initials: M
authors.lastname: González Martín
authors.forename: E
authors.initials: E
authors.lastname: Lledó
authors.forename: R
authors.initials: R
authors.lastname: Matesanz
authors.forename: R
authors.initials: R
authors.lastname: Marcén
authors.forename: P
authors.initials: P
authors.lastname: Montañés
authors.forename: J
authors.initials: J
authors.lastname: Pascual
mesh_terms: D005544:Forecasting; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000009:adverse effects / Q000706:statistics & numerical data / Q000639:trends*; D010535:Laparoscopy; D019520:Living Donors; D009369:Neoplasms / Q000209:etiology; D009392:Nephrectomy / Q000379:methods; D009926:Organ Preservation / Q000379:methods; D013030:Spain; D009927:Tissue and Organ Procurement / Q000639:trends; D014183:Transplantation, Heterologous / Q000639:trends